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Severe acute respiratory syndromewith highmortality rates (∼50%)
is associated with a novel group 2c betacoronavirus designated
Middle East respiratory syndrome coronavirus (MERS-CoV). We
synthesized a panel of contiguous cDNAs that spanned the entire
genome. Following contig assembly into genome-length cDNA,
transfected full-length transcripts recovered several recombinant
viruses (rMERS-CoV) that contained the expected marker muta-
tions inserted into the component clones. Because the wild-type
MERS-CoV contains a tissue culture-adapted T1015N mutation in
the S glycoprotein, rMERS-CoV replicated ∼0.5 log less efficiently
than wild-type virus. In addition, we ablated expression of the
accessory protein ORF5 (rMERS•ORF5) and replaced it with tomato
red fluorescent protein (rMERS-RFP) or deleted the entire ORF3, 4,
and 5 accessory cluster (rMERS-ΔORF3–5). Recombinant rMERS-
CoV, rMERS-CoV•ORF5, and MERS-CoV-RFP replicated to high titers,
whereas MERS-ΔORF3–5 showed 1–1.5 logs reduced titer compared
with rMERS-CoV. Northern blot analyses confirmed the associated
molecular changes in the recombinant viruses, and sequence analy-
sis demonstrated that RFP was expressed from the appropriate con-
sensus sequence AACGAA. We further show dipeptidyl peptidase 4
expression, MERS-CoV replication, and RNA and protein synthesis
in human airway epithelial cell cultures, primary lung fibroblasts,
primary lung microvascular endothelial cells, and primary alveolar
type II pneumocytes, demonstrating a much broader tissue tropism
than severe acute respiratory syndrome coronavirus. The avail-
ability of a MERS-CoV molecular clone, as well as recombinant
viruses expressing indicator proteins, will allow for high-throughput
testing of therapeutic compounds and provide a genetic platform
for studying gene function and the rational design of live virus
vaccines.
emerging pathogen | zoonosis | synthetic genome
Emerging respiratory virus infections can cause considerablemorbidity and mortality in human populations. Some, in-
cluding influenza A viruses and human coronaviruses (CoVs),
can spread rapidly and cause acute lung injury and its more se-
vere form, acute respiratory distress syndrome (ARDS). These
devastating end-stage lung diseases are often associated with high
mortality rates (∼30–50%) and can progress to chronic conditions
such as pulmonary fibrosis (1). CoVs frequently transmit between
species (2–4). Divided into three main groups, the betacor-
onaviruses represent a large collection of phylogenetically dis-
tant strains that include several human coronaviruses (HCoVs)
such as HCoV OC43, HCoV HKU1 (group 2a), and the severe
acute respiratory syndrome coronavirus (SARS-CoV) (group 2b)
(5). In 2003, SARS-CoV emerged from zoonotic sources in China
and caused atypical pneumonia and ARDS with 10% mortality
rates (5). In 2012, a new group 2c betacoronavirus was detected in
the Middle East (3). Designated MERS-CoV (Middle East re-
spiratory syndrome coronavirus), it has caused at least 114 con-
firmed cases with 54 deaths as of September 10, 2013. The virus
replicates efficiently in human airway epithelial cells (HAEs)
and uses human and bat dipeptidyl peptidase 4 (DPP4) as recep-
tors for entry (6, 7). Human-to-human transmission, coupled with
the unusual severity and high mortality rates, dictates a need for
key resources for the testing of MERS-CoV therapeutics and vac-
cines (8).
The 30,119-nt MERS-CoV genome encodes a typical portfolio
of ORFs expressed from both genome-length (ORF1a/1b) (9)
and subgenomic-length mRNAs (sgRNAs), which are arranged
in a nested set from the 3′ end of the genome. The MERS-CoV
transcription regulatory sequence (TRS) is predicted to be
AACGAA, but remains poorly defined in culture. In addition to
the classic structural proteins—a 180/90-kDa spike glycoprotein
(S), an ∼23-kDa membrane glycoprotein (M), a small envelope
protein (E), and an ∼50-kDa nucleocapsid protein (N)—MERS-
CoV also encodes at least four group-specific ORFs designated
ORF3, ORF4a, ORF4b, and ORF5. Previously, we constructed
or synthesized full-length infectious clones from several CoVs,
including SARS-CoV, HCoV NL63, and HKU3 (BAT-SRBD)
(10–12). In this manuscript, we describe the synthesis and assembly
of a full-length molecular clone for MERS-CoV and show that
wild-type MERS-CoV (EMC2012 substrain) has evolved a unique
tissue culture-adapted mutation in the S glycoprotein that is not
present in the recombinant virus derived from the molecular
clone. Recombinant viruses were also isolated that express a red
fluorescent indicator, tomato red (red fluorescent protein; RFP),
from sgRNA. In addition, we also generate mutants lacking one
or more of the MERS-CoV group-specific ORFs. The availability
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of a molecular clone for MERS-CoV, along with marker and
deletion viruses, provides opportunities for understanding novel
gene functions, tools for high-throughput screening of antiviral
drugs, and essential reagents for the rational design of candidate
live-attenuated virus vaccines.
Results
Design of MERS-CoV Full-Length cDNAs.Rapid response and control
of emerging respiratory viruses require high-throughput strate-
gies for the manipulation and recovery of recombinant viruses by
reverse genetic strategies. The MERS-CoV genome was initially
synthesized as a panel of six contiguous cDNAs (A–F) that span
the genome and are linked by class II restriction endonuclease
sites (BglI-GCCNNNN↓NGGC), which cleave at symmetrical pal-
indromic sequences but leave different asymmetric 3-nt overhangs.
Due to instability in the plasmid, the D fragment was split into
two separate fragments, resulting in seven total cDNA cassettes
(Fig. 1). Thus, rational cDNA design allows for the systematic,
directional, and efficient assembly of the individual MERS A–F
cDNAs into a genome-length cDNA by in vitro ligation (12). In
addition, naturally occurring BglI sites were removed by G-C
and C-T changes at positions 494 and 17713, respectively, and
an A-G change was introduced at position 2393 to ablate a poten-
tial T7 pause site in the derived synthetic molecular clone (12). The
MERS D fragment was unstable in microbial vectors and was thus
bisected into two pieces, designated MERS D1 and MERS D2,
which were very stable. BglI sites were engineered by introducing
silent mutations between the A/B, B/C, C/D1, D1/D2, D2/E, and
E/F junctions (Fig. 1). The MERS A fragment contains a T7 start
site, whereas the F subclone terminates in 25 T residues, allowing
for in vitro transcription of capped, polyadenylated transcripts.
Characterization of Recombinant Viruses. To assemble the MERS-
CoV molecular clone, each subclone was digested with BglI,
purified, and ligated, and the resulting product was used as a
template for in vitro transcription. Because N gene transcripts
enhance the infectivity of CoV full-length transcripts (12), re-
combinant (rMERS-CoV) transcripts were mixed with capped
N transcripts and electroporated into Vero cells. Within 48–72 h
posttransfection, cytopathic effects and leader-containing tran-
scripts were detected within transfected cultures but not in controls.
rMERS-CoV replicated to titers that approach 107 to 108 pla-
que-forming units/mL (pfu/mL) and formed small plaques in
Vero 81 cells (Figs. 2 and 3). rMERS-CoV, but not wild-type
virus, should encode several unique marker mutations at the
junctions associated with the assembly of the component clones.
Therefore, RT-PCR was used to generate cDNA amplicons,
which were purified and then subjected to restriction fragment
length polymorphism (RFLP) analysis with BglI. MERS-CoV
contains a BglI site at position 17717 that was ablated in
rMERS-CoV (Fig. 2B). In contrast, rMERS-CoV contains a BglI
site inserted between the component E/F junctions (Fig. 2C),
a genotype that was subsequently verified by genome-length
sequence analysis.
Interestingly, wild-type MERS-CoV appeared to replicate
∼0.5 log more efficiently and formed larger plaques than
rMERS-CoV (Figs. 2 and 3). Genome-length sequence analysis
of our passage 9 wild-type MERS-CoV stock revealed a unique
consensus T1015N change in the S glycoprotein that was not
present in the published sequence. To evaluate whether this con-
sensus mutation altered virus growth kinetics or plaque morphol-
ogy in vitro, we introduced this mutation into the molecular clone
and isolated a recombinant virus (rMERS-CoV T1015N). rMERS-
CoV T1015N more closely replicated wild-type virus replication
kinetics and plaque formation (Figs. 2D and 3E). These data
suggest that T1015N is a tissue culture-adapted mutation that arose
during serial in vitro passage.
rMERS-CoV Derivative Virus Phenotypes. The MERS-CoV genome
encodes several accessory ORFs of unknown function. To eval-
uate the roles of these accessory ORFs in MERS-CoV replica-
tion, we introduced a stop codon into ORF5 at nucleotide A27162G
(rMERS-CoV•ORF5), which truncated ORF5, replaced ORF5
with the RFP gene (rMERS-CoV-RFP), or deleted the down-
stream subgenomic ORFs 3, 4a, 4b, and 5 (rMERS-CoV-ΔORF3–
5). Following electroporation of full-length transcripts into Vero
cells, recombinant viruses were isolated. Compared with rMERS-
CoV, rMERS-CoV•ORF5 and rMERS-CoV-RFP replicated to
titers from 107 to 108 pfu/mL. In contrast, the replication of
rMERS-CoV-ΔORF3–5 was significantly reduced by ∼1–1.5 logs
in Vero cells (Fig. 2A). Consonant with the presence of sgRNA
transcripts encoding RFP, fluorescent microscopy revealed RFP
fluorescence at different times postinfection in rMERS-CoV-RFP
but not in rMERS-CoV– or wild-type control-infected cultures
(Fig. 3 A–D). To evaluate virus RNA synthesis, Northern blot
analyses revealed the expected set of appropriately sized RNAs
in wild-type MERS-CoV–, rMERS-CoV–, rMERS-CoV-RFP–,
and rMERS-CoV•ORF5–infected cells, which included genome-
length RNA and seven sgRNAs (Fig. 4A). As RFP and ORF5
are of similar size, we did not note any visible alterations in the
size of sgRNA5 between these two viruses. In contrast, rMERS-
CoV-ΔORF3–5 removed several ORFs and TRSs from the ge-
nome, resulting in a loss of sgRNAs 3, 4, and 5 and increased
expression and mobility of sgRNA2 (S glycoprotein) (Fig. 4A).
To evaluate recombinant virus structural protein expression,
we cloned and expressed the MERS-CoV S and N proteins in
Venezuelan equine encephalitis virus strain 3526 replicon con-
structs [virus replicon particle (VRP)-S, VRP-N], inoculated
mice, and isolated antisera against these viral proteins. Using
Western blot analysis, we confirmed robust S-glycoprotein and
N-protein expression in wild-type MERS-CoV–, rMERS-CoV–,
rMERS-CoV•ORF5–, rMERS-CoV-RFP–, and rMERS-CoV-
ΔORF3–5–infected cells (Fig. 4B). Interestingly, increased
S-glycoprotein expression was noted in rMERS-CoV-Δ3–5–
infected cells, a phenotype coincident with increased sgRNA2
expression (Fig. 4B). The MERS-CoV S glycoproteins are cleaved
more efficiently at later times and were heavily glycosylated, as
evidenced by increased electrophoretic mobility following peptide-
N-glycosidase F (PNGase F) treatment (Fig. S1). As downstream
Fig. 1. Organization of the MERS-CoV molecular clone. (A) The organiza-
tion of the MERS-CoV genome. (B) The full-length MERS-CoV genome was
ultimately divided into seven contiguous cDNAs designated MERS A–F and
flanked by unique BglI sites that allow for directed assembly of a full-length
cDNA: MERS A (nucleotides 1–4692), MERS-B (4693–8811), MERS-C (8812–12258),
MERS-D1 (12259–15470), MERS-D2 (15471–18806), MERS-E (18807–24397),
and MERS-F (24398–30119).
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TRSs are thought to influence the abundance of upstream tran-
scripts, it seems likely that the deletion of the regulatory domains
of sgRNAs 3, 4, and 5 enhanced the expression of sgRNA2, resulting
in increased S-glycoprotein expression and fusion phenotypes. An
increased fusion phenotype was noted in rMERS-CoV-ΔORF3–5
that was rarely evident in wild-type or recombinant control virus-
infected cells (Fig. 4 C and D).
Recombinant Virus Growth in Primary Lung Cultures. MERS-CoV
has been reported to replicate in nonciliated HAEs and alveolar
type II pneumocytes in ex vivo cultures (7, 13). To evaluate
MERS-CoV tissue specificity in other lung cells, we obtained
primary human lung fibroblasts, microvascular endothelial cells,
alveolar type II pneumocytes, and ciliated HAEs and infected
these cultures with MERS-CoV, rMERS-CoV-RFP, or rSARS-
CoV. Wild-type MERS-CoV titers increased during infection in
alveolar type II pneumocytes, microvascular endothelial cells,
HAEs, and fibroblasts, approaching titers of 106 to 107 pfu/mL
within 30 h postinfection (Fig. 5). RFP expression was clearly
visible in fibroblast and ciliated HAE cultures but not in endo-
thelial cells or alveolar type II pneumocytes, most likely due to
high autofluorescence levels in these cultures (Fig. 6A). MERS-
CoV replicated most efficiently in HAE and lung fibroblast
cultures, slightly less efficiently in type II pneumocytes, and least
efficiently in microvascular endothelial cells. Under identical
conditions, SARS-CoV only replicated efficiently in the HAE
cultures. To confirm robust MERS-CoV replication, we per-
formed Northern blot analysis and clearly demonstrated the
presence of both full-length and subgenomic-length MERS-CoV
transcripts during virus infection of the primary lung cell types
tested, with the exception of undifferentiated human bronchial
cells (Fig. 6B). Consonant with these data, real-time RT-PCR
and Western blot analysis demonstrated DPP4 mRNA and
protein expression in all these cell types (Fig. 6 C and D).
Discussion
Rapid-response platforms are needed to control newly emerg-
ing virus pathogens. MERS-CoV likely emerged in the Middle
East from exotic animals, perhaps bats, although the exact timing
and origins of this pathogen in human populations remains un-
clear and is under study. MERS-CoV has caused 54 deaths at
the time of writing (∼50% mortality), including documented
instances of human-to-human transmission (3, 8). Therefore, the
epidemic potential of MERS-CoV is high and its biology, life
cycle, gene function, and pathogenic mechanisms clearly warrant
additional study.
Developing full-length infectious cDNAs of emerging RNA
viruses is assisted by the availability of high-throughput se-
quencing, gene synthesis, and the use of class II/IIS restriction
endonucleases that allow seamless assembly of consensus syn-
thetic cDNA fragments into full-length infectious cDNAs. In this
instance, we synthesized a molecular clone from the published
sequence, assembled full-length genomes, and isolated recombi-
nant viruses in culture. Recently, similar approaches have been
applied to newly emerging influenza viruses and can direct the
rapid assembly of genome-length microbial genomes exceeding
millions of base pairs (10, 12, 14). It is noteworthy that rMERS-
CoV replicated less efficiently than wild-type MERS-CoV, a phe-
notype that was linked to a tissue culture-adapted mutation in the
S2 glycoprotein of the passage 9 stock of wild-type virus. S2 con-
tains the fusion peptide, transmembrane domain, and two heptad
repeat regions (HR1 and HR2), conserved features of class I fu-
sion proteins that form the classic six-helix bundle believed to
drive virion–cell membrane fusion (15). As substitutions in S2 may
alter properties of S1 and S including stabilizing S1–S2 association,
altering fusion behavior, and changing tissue tropism (16), it is
likely that the T1015N mutation enhances entry and/or egress
phenotypes in vitro. Although the origin of the tissue-culture ad-
aptation is unclear, other studies have demonstrated the rapid
emergence of tissue-culture adaptations in the M and S glyco-
proteins of human and zoonotic strains of SARS-CoV (17, 18).
As our stock was derived from an inoculum used for primate
experiments (19), it is possible that this tissue-culture adaptation
altered MERS-CoV pathogenic outcomes after in vivo infection.
MERS-CoV, like other CoVs, expresses full-length and sgRNAs
arranged in the form of a nested set from the 3′ end of the
Fig. 2. Recombinant virus growth. (A) Cultures of Vero 81 cells were
infected with MERS-CoV, rMERS-CoV, rMERS-CoV•ORF5, rMERS-CoV-RFP,
and rMERS-CoV-ΔORF3–5 at an MOI of 0.01. Virus samples were harvested at
different times postinfection and titered by plaque assay (■, MERS-CoV; □,
rMERS-CoV; ▲, rMERS-CoV•ORF5; Δ, rMERS-CoV-RFP; ●, rMERS-CoV-
ΔORF3–5). (B) RFLP analysis spanning a naturally occurring BglI site at
∼17,717 bp that is ablated in rMERS-CoV; uncut vs. digested with Bgll. (C)
RFLP analysis across the engineered rMERS-CoV E/F junction at approximately
nucleotide 24397 either uncut or cut with Bgll. (D) Wild-type MERS-CoV,
rMERS-CoV, and rMERS-CoV T1015N growth were compared in triplicate in
Vero 81 cells (■, MERS-CoV; □, rMERS-CoV; ▲, rMERS-CoV T1015N). Error
bars represent SD from the mean.
Fig. 3. rMERS-CoV-RFP expression and comparative plaque morphology.
(A–D) Cultures of Vero cells were infected with rMERS-CoV-RFP (A and C) or
rMERS-CoV (B and D). At 12 h postinfection, the cultures were visualized
for tomato red fluorescence (A and B) or by light microscopy (C and D). (E)
Plaque size differences between wild-type MERS-CoV, rMERS-CoV, and
rMERS-CoV T1015N.
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genome. The expression of sgRNAs is regulated by coordinated
interactions between TRSs located at the 5′ end of the genome
and just upstream of many downstream ORFs. Sequence analysis
of a subset of the 5′ ends of sgRNAs encoding natural or in-
dicator transgenes indicates that the core sequence AACGAA
functions as a site for discontinuous transcription during nega-
tive-strand synthesis. MERS-CoV encodes several unique group-
specific ORFs. Deletion analysis clearly demonstrates that these
group-specific ORFs are not essential for virus replication, al-
though the absence of these genes as a group attenuates peak
viral titers (Fig. 2A). It is interesting that deletion of ORFs 3–5
resulted in enhanced expression of sgRNA2, which encodes the S
glycoprotein. These findings are consistent with a model of dis-
continuous transcription during negative-strand synthesis, where
downstream TRSs influence the abundance of upstream tran-
scripts (20). Increased sgRNA2 transcript production resulted in
enhanced S-glycoprotein expression that was associated with
increased syncytial formation following MERS-CoV-ΔORF3–5
infection (Fig. 4D). Increased syncytia formation and in vitro
cytotoxicity may translate to improved cell-to-cell spread and/or
altered in vivo pathogenesis, but this phenotype is complicated
by the loss of several group-specific ORFs. Wild-type and re-
combinant S glycoprotein is heavily glycosylated in vitro, as
PNGase F removes N-linked glycosylation moieties and reduces
S-glycoprotein molecular weights by ∼50 kDa. According to the
NetOGlyc 4.0 Server (www.cbs.dtu.dk/services/NetOGlyc), the
MERS-CoV S glycoprotein is also predicted to encode three O-
linked glycosylation sites, so PNGase F treatment will likely not
remove all carbohydrate moieties.
Currently, the functions of the MERS-CoV group-specific
ORFs are unknown, but by analogy with other CoVs, they likely
encode structural proteins or IFN antagonist genes that modulate
in vivo replication efficiency and/or pathogenesis (21). Unfortu-
nately, we have not been able to demonstrate MERS-CoV rep-
lication in standard laboratory strains of Mus mus musculus,
M. m. domesticus, or M. m. castaneus mice, nor have we been
able to establish infections in immune-deficient mice, perhaps
due to problems in receptor binding and entry (7). In support
of this hypothesis, sequence and structural comparisons of the
SARS-CoV S-glycoprotein receptor-binding domain bound with
human DPP4 receptor reveal differences between several key
interface residues in mouse DPP4 compared with human DPP4
that likely disrupt binding (22). The development of a macaque
model (19), coupled with a robust genetic system for MERS-
CoV, provides a platform for evaluating the underlying roles of
MERS-CoV genes in viral pathogenesis in vivo.
SARS-CoV primarily targeted ciliated HAEs and type 1 and 2
pneumocytes in the lung (13, 23). In ex vivo human lung cultures,
MERS-CoV is reported to infect and replicate in nonciliated
bronchial epithelium, bronchiolar epithelial cells, alveolar epi-
thelial cells, and perhaps endothelial cells (13). Previously, we
demonstrated that HAEs provide a robust primary cell substrate
for culturing uncultivable viruses such as human CoVs (11). We
extend these studies by demonstrating DPP4 transcript, protein
expression, and MERS-CoV replication in purified primary al-
veolar type II pneumocytes and microvascular endothelial and
fibroblast cultures. Under identical conditions, SARS-CoV did
not replicate efficiently in microvascular endothelial and fibroblast
cultures, likely reflecting the unique tissue expression patterns of
Fig. 4. Recombinant virus phenotypes. Cultures of cells were infected with
MERS-CoV or recombinant derivative viruses, and intracellular RNA was
harvested and analyzed by Northern blot (A; lane 1, MERS-CoV; lane 2,
rMERS-CoV; lane 3, rMERS-CoV•ORF5; lane 4, rMERS-CoV-RFP; lane 5, rMERS-
CoV-ΔORF3–5; lane 6, uninfected control). In parallel, cell lysates were re-
solved by SDS/PAGE and probed with anti-S and anti-N antibodies; increased S-
but not N-protein expression levels were apparent in rMERS-CoV-ΔORF3–5–
infected cells (B). B includes an actin control. rMERS-CoV-ΔORF3–5–infected
cells (D) displayed an increased fusion phenotype compared with the parental
control (C).
Fig. 5. Recombinant virus growth in primary human lung cells. HAEs, pri-
mary alveolar type II pneumocytes, primary lung microvascular endothelial
cells, and primary lung fibroblast cells were infected with wild-type rSARS-
CoV, wild-type MERS-CoV, or rMERS-CoV-RFP. (A) Wild-type MERS-CoV and
SARS-CoV growth kinetics in HAEs. Data are representative of two inde-
pendent experiments. Error bars represent SD from the mean. Green bars,
wild-type SARS-CoV; pink bars, wild-type MERS-CoV. (B) Wild-type SARS-
CoV, wild-type MERS-CoV, and rMERS-CoV-RFP growth kinetics were com-
pared in alveolar type II (ATII) pneumocytes, lung microvascular endothelial
(MVE) cells, and lung fibroblasts (FBs). SARS-CoV did not replicate in any of
the primary cell types examined in B. Cells were specific to one of two
donors, and neither was permissive for SARS-CoV. Data are representative of
two independent experiments. Error bars represent SD from the mean. The
dotted black line in B represents the limit of detection for the assay. All
points under this line are considered to be negative for replication in the
samples assayed. Solid blue line with closed diamond, wild-type MERS-CoV in
ATII cells; dotted blue line with closed diamond, rMERS-CoV-RFP in ATII cells;
solid blue line with open diamond, wild-type SARS-CoV in ATII cells (did not
replicate); solid pink line with closed triangle, wild-type MERS-CoV in FB
cells; dotted pink line with closed triangle, rMERS-CoV-RFP in FB cells; solid
pink line with open triangle, wild-type SARS-CoV in FB cells (did not repli-
cate); solid black line with closed circle, wild-type MERS-CoV in MVE cells;
dotted black line with closed circle, rMERS-CoV-RFP in MVE cells; solid black
line with open circle, wild-type SARS-CoV in MVE cells (did not replicate).
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the angiotensin-converting enzyme 2 and DPP4 receptors. Using
this patient code, we did not observe SARS-CoV replication in
alveolar type II pneumocytes, nor did we detect robust MERS-
CoV replication in nondifferentiated human bronchial epithelial
(HBE) cells. As previously noted (24), genetic susceptibility allele
patterns in different patient codes might influence virus infection
outcomes and replication efficiency. The data likely underscore
the importance of correlating CoV infectivity patterns with DPP4
and TMPRSS2 expression in human tissues (25). Although spec-
ulative, the demonstration of efficient MERS-CoV replication in
endothelial cells may provide a pathway for spread from the lung
to other organs. Interestingly, highly pathogenic H5N1 strains also
replicate efficiently in microvascular endothelial cells, potentially
providing a pathway for systemic spread to other organs (26, 27).
The availability of a MERS-CoV molecular clone and recom-
binant viruses expressing indicator genes such as RFP provides
important tools for high-throughput screening of candidate anti-
viral agents such as IFN, kinase inhibitors, and inhibitors of viral
cellular proteases that are essential for polyprotein processing or
virus docking and entry into cells. The molecular clone will assist
in the identification and validation of genes targeted by antivirals
and in the discovery of virally encoded functions important for
virus replication and pathogenesis. Finally, the molecular clone
may provide the capacity to rationally design live-attenuated virus
vaccines (28) or safer seed stocks for killed vaccines that lack
genes or genetic functions that are critical for regulating in vivo
pathogenesis for other alpha- and betacoronaviruses.
Materials and Methods
Virus and Cells. The wild-type EMC2012 strain of MERS-CoV (passage 8,
designated MERS-CoV) was provided by Bart Haagmans (Erasmus University,
Rotterdam). Virus stocks (passage 9) were propagated on Vero 81 cells (CCL-
81; ATCC) in reduced-serum minimal essential medium (Opti-MEM) con-
taining 4% (vol/vol) fetal clone II serum (HyClone/Gibco) and supplemented
with kanamycin (0.25 μg/mL) and gentamycin (0.05 g/mL) at 37 °C in a hu-
midified CO2 incubator. For wild-type and recombinant virus growth, cul-
tures of Vero cells were infected at a multiplicity of infection (MOI) of 0.01 or
1.0 as indicated for 1 h, and samples were titered by plaque assay. Re-
combinant SARS-CoV strain Urbani was propagated on Vero E6 cells in MEM
containing 10% fetal clone II serum and supplemented with kanamycin and
gentamycin. Virus plaques were visualized by neutral red staining at 2–3 d
postinfection. Virus was maintained under biosafety level (BSL)3 conditions
with redundant fans, and personnel used powered-air purifying respirators
and Tyvek suits.
Human lungs were obtained under protocol 03-1396, which was approved
by the University of North Carolina at Chapel Hill Biomedical Institutional
Review Board, and donors gave informed consent. Tracheo-bronchial and
alveolar epithelial cells were obtained and cultured (29, 30). Human lung
microvascular endothelial cells were obtained by dispase and elastase di-
gestion of peripheral lung tissue stripped of the visceral pleura, followed by
primary culture in EGM-2 media plus FBS (Lonza). The cells were subjected to
two or three rounds of CD31 bead purification (Dynabeads; Life Technolo-
gies/Invitrogen), after which they were >95% CD31-positive as measured by
flow cytometry and used between passages 5 and 10. Primary human lung
fibroblasts were obtained by outgrowth from finely minced distal human
lung tissues onto scratched type 1/3 collagen-coated dishes in Dulbecco’s
modified Eagle medium with high glucose (DMEMH) media plus 10% FBS,
antibiotics, and antimycotics. Primary isolated cells were obtained by treat-
ment with trypsin/EDTA and subcultured as above. The cells exhibited typical
fibroblast morphology and were negative for CD31 and pan-cytokeratin as
assessed by flow cytometry and immunofluorescence staining. To evaluate
dipeptidyl peptidase 4 expression from primary lung cultures, RNA was re-
verse-transcribed (SuperScript III; Invitrogen) and then subjected to quanti-
tative RT-PCR analysis for DPP4 copy-number determination (iQ SYBR Green
Supermix; Bio-Rad). Primers were as follows: DPP4F (5′-ccaaagactgtacgggt-
tcc-3′) and DPP4R (5′-acaaagaactttacagttggattcac-3′); and GAPDHF (5′-agc-
cacatcgctcagacac-3′) and GAPDHR (5′-gcccaatacgaccaaatcc-3). Raw DPP4 results
were normalized to GAPDH and fit to a standard curve made using plasmids
encoding DPP4.
Systematic Assembly of a Full-Length MERS-CoV cDNA. The clone was designed
and purchased from Bio Basic as six contiguous cDNAs flanked by unique
class II restriction endonuclease sites (BglI). We used published sequence
information from an earlier reported passage (9). The MERS D fragment
was unstable and subsequently subdivided into two subclones designated
MERS D1 and D2 containing mutations G494C and G17713T to disrupt two
naturally occurring BglI sites and an A2849G mutation to disrupt a stretch
of eight A residues, which might interfere with in vitro RNA transcription
reactions. In addition, several silent mutations were included to produce
unique BglI sites at appropriate locations across the genome (Fig. 1). The
MERS A–F inserts were restriction-digested, resolved on 0.8% agarose gels,
and visualized, excised, and purified using a QIAquick Gel Extraction Kit
(Qiagen). The MERS A–F inserts were mixed and ligated overnight at 4 °C,
phenol/chloroform-extracted, and precipitated with isopropyl alcohol. Full-
length T7 transcripts were generated in vitro as described by the manufac-
turer (Ambion; mMessage mMachine) with certain modifications (12). For
MERS-CoV N transcripts, 1 μg of plasmid DNA encoding the N gene (ampli-
fied using forward primer 5′-atttaggtgacactatagatggcatcccctgctgcacc-3′ and
reverse primer 5′-ttttttttttttttttttttttctaatcagtgttaacatcaatcattgg-3′) was
transcribed by SP6 RNA polymerase with a 4:1 ratio of cap analog to GTP.
Recombinant MERS-CoV Deletion and Expression Constructs. The reported
sequence of MERS-CoV strain EMC2012 identified a mutation at position
G27162A, which resulted in a stop codon at position 108 in ORF5 and which
had been incorporated into the synthetic clone, resulting in the rMERS-
CoV•ORF5 recombinant. To restore ORF5, the MERS F plasmid was PCR-
amplified with either primer set EMC F+1865 (5′-tccaaccaacacactatgtc-3′)
and EMC F-2820 (5′-nnnnnngctcttcaaagtattatgaggataactaag-3′) or set EMC F+
2830 (5′-nnnnnngctcttcactttggtttgtagatagaattcg-3′) and EMC F-3941 (5′-ca-
ccgaaatgcatgccagcc-3′). To make rMERS-CoV wild-type virus, the two PCR
amplicons were digested with SapI, ligated together, digested with PflMI,
and then cloned into PflMI-digested F plasmid. Sequence analysis of MERS-
CoV EMC2012 p9 material also revealed a consensus T1015N mutation in the
S glycoprotein that was not present in the cDNA clone. We used standard
recombinant DNA approaches to produce the rMERS-CoV T1015N virus.
To replace ORF5 with the RFP gene, one amplicon was generated by
amplifying the F plasmid with primers EMC F+1376 (5′-gtttctgtcgatcttgagtc-
3′) and F2463Rev (5′-nnnnnncgtctcaccatagttcgttaaaatcctgg-3′). A second PCR
Fig. 6. Recombinant virus expression in primary human lung cells. (A and B)
HAE and FB cultures were infected with rMERS-CoV-RFP and visualized by
fluorescent microscopy [20×; (A, a) HAE, 48 h; (A, b) HAE, 72 h; (A, c) FB, 48 h;
(A, d) FB, 72 h]. MERS-CoV intracellular RNA was harvested and analyzed by
Northern blot (B; lane 1, primary alveolar type II pneumocytes; lane 2, pri-
mary lung fibroblasts; lane 3, primary undifferentiated airway epithelium;
lane 4, primary lung microvascular endothelial cells). Images are represen-
tative of two independent experiments. (C and D) Real-time RT-PCR and
Western blot analysis of DPP4 expression in primary human cells. AT2, al-
veolar type II pneumocytes; HAE, human airway epithelial cells under an air–
liquid interface.
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amplified the RFP gene with primers tRFPbsmb (5′-nnnnnncgtctctatggt-
gagcaagggcgagg-3′) and tRFP rev (5′-nnnnnngggacccttacttgtacagctcgtccatg-
3′). The two amplicons were digested with BsmBI and then joined with T4
DNA ligase. The product was digested with PacI and SanDI and ligated into
the MERS F plasmid using standard techniques. To delete ORFs 3–5, the
MERS F plasmid was amplified with primer M13F1 and primer EMC F-1140
(5′-nnnnnngggaccctaattagtgaacatgaaccttatg-3′). This product was digested
with NruI and SanDI and ligated into the MERS F plasmid.
Transfection of Full-Length Transcripts. RNA transcripts were added to 800 μL
of Vero cell suspension (8.0 × 106 cells) in an electroporation cuvette, and
four electrical pulses of 450 V at 50 μF were delivered with a Gene Pulser II
electroporator (Bio-Rad). The transfected Vero cells were allowed to recover
for 10 min at room temperature and then incubated at 37 °C for 2–4 d in
a 75-cm2 flask. Virus progeny was then passaged one time in Vero cells for
48 h and used to generate a stock for future use.
Restriction Fragment Length Polymorphism Analysis. To detect leader-con-
taining RNAs, intracellular RNA from wild-type, rMERS-CoV, and derivative
viruses was reverse-transcribed with a primer at the 3′ end of the genome
and cDNA was isolated for PCR using a reverse primer located in ORF5 and
a forward primer located in the leader RNA sequence at the 5′ end of the
genome (5′-ctatctcacttcccctcgttctc-3′). Leader-containing amplicons were
sequenced (14). For RT-PCR restriction length polymorphism analysis, primers
EMC 36F (5′-ccgatattctggtggttgat-3′) (nucleotides 17310–17329 genome)
and EMC 37R (5′-atcgagtttaaagcccatcc-3′) (nucleotides 18171–18190 ge-
nome) were used to amplify an ∼880-bp–long amplicon spanning a naturally
occurring BglI site at nucleotide 17717 (9). In addition, primers EMC 50F (5′-
ccaatttacgccaggatgat-3′) (nucleotides 23968–23987) and EMC 51R (5′-att-
aagggaggtaatgggct-3′) (nucleotides 25039–25058) amplified an ∼1,090-bp
region that spans the E/F junction in recombinant MERS-CoV (nucleotide
24397). Wild-type MERS-CoV cDNA product cannot be cleaved with BglI in
this region, whereas the recombinant virus PCR amplicon contains an engi-
neered BglI site between nucleotides 24391 and 24401.
Northern and Western Blot Analysis. At 12 h postinfection, intracellular RNA
was isolated using TRIzol reagent (Invitrogen). RNA (∼0.1 μg) was treated
with glyoxal and separated on agarose gels using NorthernMax-Gly according
to the manufacturer’s directions (Ambion). The RNA was transferred to
a BrightStar-Plus membrane (Ambion) for 3–4 h and then cross-linked to the
membrane using UV light. The blot was prehybridized and probed with
a MERS-CoV N gene-specific biotinylated oligodeoxynucleotide probe. After
washing, filters were incubated with streptavidin-alkaline phosphatase,
washed, and then incubated with the chemiluminescent substrate CDP-Star
(Sigma). The blots were overlaid with film and developed.
For Western blot analyses, 12 h postinfection, wild-type MERS-CoV–, rMERS-
CoV–, rMERS-CoV-RFP–, rMERS-CoV•ORF5–, and rMERS-CoV-ΔORF3–5–infected
cells were washed in 1× PBS and lysed in buffer containing 20 mM Tris·HCl (pH
7.6), 150 mM NaCl, 0.5% deoxycholine, 1% Nonidet P-40, and 0.1% SDS. Post-
nuclear supernatants were then added to an equal volume of 5mMEDTA, 0.9%
SDS, resulting in a final SDS concentration of 0.5%. Samples were then heat-
inactivated for 30 min at 90 °C at BSL3 before removal. At BSL2, samples were
again heat-inactivated for 30 min at 90 °C before use. Equivalent sample vol-
umes were loaded onto 7.5% Criterion gradient gels (Bio-Rad) and transferred
to PVDF membranes (Bio-Rad). For detecting MERS-CoV antigens, blots were
probed with polyclonal mouse antisera obtained after vaccination of mice with
Venezuelan equine encephalitis virus replicon particles that express the MERS-
CoV S glycoprotein (VRP-S) or N protein (VRP-N) (each diluted 1:400) and de-
veloped using ECL chemiluminescence reagents (Amersham Biosciences). Anti-
serumagainstmouse actin proteins was used as a control. For detection of DPP4
protein, a DPP4 antibody (LifeSpan BioSciences) or GAPDH mouse mono-
clonal antibody was used for Western blot analysis (1:10,000; Sigma).
ACKNOWLEDGMENTS. We thank the University of North Carolina (UNC)
Lineberger Comprehensive Cancer Center DNA Sequencing Facility, the Nucleic
Acids Division of the Lineberger Tissue Culture Facility, the UNC Cystic Fibrosis
Tissue Procurement and Cell Culture Core for providing primary human
cells, the UNC Nucleic Acid Core, and the UNC Genome Analysis Facility.
This work was supported by grants from the National Institutes of Health
(U19AI100625, U19AI107810, AI108197, and AI085524) and Defense Threat
Reduction Agency (DTRA) HDTRA1-12-C-0035.
1. Tsushima K, et al. (2009) Acute lung injury review. Intern Med 48(9):621–630.
2. Baric RS, Yount B, Hensley L, Peel SA, Chen W (1997) Episodic evolution mediates
interspecies transfer of a murine coronavirus. J Virol 71(3):1946–1955.
3. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA (2012) Isolation
of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med
367(19):1814–1820.
4. Huynh J, et al. (2012) Evidence supporting a zoonotic origin of human coronavirus
strain NL63. J Virol 86(23):12816–12825.
5. Perlman S, Netland J (2009) Coronaviruses post-SARS: Update on replication and
pathogenesis. Nat Rev Microbiol 7(6):439–450.
6. Gierer S, et al. (2013) The spike protein of the emerging betacoronavirus EMC uses
a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted
by neutralizing antibodies. J Virol 87(10):5502–5511.
7. Raj VS, et al. (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging
human coronavirus-EMC. Nature 495(7440):251–254.
8. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM (2013) Family
cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med
368(26):2487–2494.
9. van Boheemen S, et al. (2012) Genomic characterization of a newly discovered co-
ronavirus associated with acute respiratory distress syndrome in humans. MBio 3(6):
e00473-12.
10. Becker MM, et al. (2008) Synthetic recombinant bat SARS-like coronavirus is infectious
in cultured cells and in mice. Proc Natl Acad Sci USA 105(50):19944–19949.
11. Donaldson EF, et al. (2008) Systematic assembly of a full-length infectious clone of
human coronavirus NL63. J Virol 82(23):11948–11957.
12. Yount B, et al. (2003) Reverse genetics with a full-length infectious cDNA of severe
acute respiratory syndrome coronavirus. Proc Natl Acad Sci USA 100(22):12995–13000.
13. Chan RW, et al. (2013) Tropism of and innate immune responses to the novel human
betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol
87(12):6604–6614.
14. Yount B, Roberts RS, Lindesmith L, Baric RS (2006) Rewiring the severe acute re-
spiratory syndrome coronavirus (SARS-CoV) transcription circuit: Engineering a re-
combination-resistant genome. Proc Natl Acad Sci USA 103(33):12546–12551.
15. Bosch BJ, et al. (2004) Severe acute respiratory syndrome coronavirus (SARS-CoV)
infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl
Acad Sci USA 101(22):8455–8460.
16. McRoy WC, Baric RS (2008) Amino acid substitutions in the S2 subunit of mouse
hepatitis virus variant V51 encode determinants of host range expansion. J Virol
82(3):1414–1424.
17. Rockx B, et al. (2007) Synthetic reconstruction of zoonotic and early human severe
acute respiratory syndrome coronavirus isolates that produce fatal disease in aged
mice. J Virol 81(14):7410–7423.
18. Pacciarini F, et al. (2008) Persistent replication of severe acute respiratory syndrome
coronavirus in human tubular kidney cells selects for adaptive mutations in the
membrane protein. J Virol 82(11):5137–5144.
19. Munster VJ, de Wit E, Feldmann H (2013) Pneumonia from human coronavirus in
a macaque model. N Engl J Med 368(16):1560–1562.
20. Sawicki SG, Sawicki DL (2005) Coronavirus transcription: A perspective. Curr Top Mi-
crobiol Immunol 287:31–55.
21. Totura AL, Baric RS (2012) SARS coronavirus pathogenesis: Host innate immune re-
sponses and viral antagonism of interferon. Curr Opin Virol 2(3):264–275.
22. Wang N, et al. (2013) Structure of MERS-CoV spike receptor-binding domain com-
plexed with human receptor DPP4. Cell Res 23(8):986–993.
23. Dijkman R, et al. (2013) Isolation and characterization of current human coronavirus
strains in primary human epithelial cell cultures reveal differences in target cell tro-
pism. J Virol 87(11):6081–6090.
24. Sims AC, et al. (2013) Release of severe acute respiratory syndrome coronavirus nu-
clear import block enhances host transcription in human lung cells. J Virol 87(7):
3885–3902.
25. Leow MK (August 13, 2013) Correlating cell line studies with tissue distribution of
DPP4/TMPRSS2 and human biological samples may better define the viral tropism of
MERS-CoV. J Infect Dis, 10.1093/infdis/jit330.
26. Zeng H, et al. (2012) Human pulmonary microvascular endothelial cells support pro-
ductive replication of highly pathogenic avian influenza viruses: Possible involvement
in the pathogenesis of human H5N1 virus infection. J Virol 86(2):667–678.
27. Chan MC, et al. (2009) Influenza H5N1 virus infection of polarized human alveolar
epithelial cells and lung microvascular endothelial cells. Respir Res 10:102.
28. Graham RL, et al. (2012) A live, impaired-fidelity coronavirus vaccine protects in an
aged, immunocompromised mouse model of lethal disease. Nat Med 18(12):
1820–1826.
29. Fulcher ML, Randell SH (2013) Human nasal and tracheo-bronchial respiratory epi-
thelial cell culture. Methods Mol Biol 945:109–121.
30. Bove PF, et al. (2010) Human alveolar type II cells secrete and absorb liquid in re-
sponse to local nucleotide signaling. J Biol Chem 285(45):34939–34949.
16162 | www.pnas.org/cgi/doi/10.1073/pnas.1311542110 Scobey et al.
